Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

NCT05913817 is registered in ClinicalTrials.gov with Jamp Pharma Corporation as lead sponsor.

NCT NCT05913817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05913817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
Lead sponsor
Jamp Pharma Corporation
Phase
Observational
Overall status
Completed
Start date
January 9, 2023
Completion date
August 25, 2025
Enrollment
324 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, crohn disease, hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis